Long-term Extension to a Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin in Subjects With Chronic Hepatitis C (CHC) Virus Genotype 1 Infection
Latest Information Update: 03 Nov 2017
At a glance
- Drugs Miravirsen (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 30 Oct 2017 Status changed from active, no longer recruiting to completed.
- 30 Oct 2017 Status changed from active, no longer recruiting to completed.
- 23 Jul 2015 Planned End Date changed from 1 Jan 2017 to 1 Nov 2016, as reported by ClinicalTrials.gov (NCT02508090)